Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3- Dose Regimen of V160 (Cytomegalovirus [CMV] Vaccine) in Healthy Seronegative Women, 16 to 35

Project: Research project

Project Details

StatusFinished
Effective start/end date4/24/18 → 4/23/23

Funding

  • Merck Sharp and Cohme Corporation: $6,500.00